Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Clinical trial NCT05491811 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05491811
- Sponsor
- Sun Yat-sen University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-01
- Primary completion
- 2024-08-31
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.